Abcam, ab282584, Anti-GLG1 antibody [EPR24347-15] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal GLG1 antibody. Carrier free. Suitable for ICC/IF, IP, WB, IHC-P and reacts with Mouse, Human, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24347-15,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, ICC/IF, IP, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab282584 is the carrier-free version of
ab271182
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GLG1 also known as Golgi apparatus protein 1 or p58 is a transmembrane protein with a molecular weight of about 150 kDa. It expresses abundantly in the Golgi apparatus where it functions in the sorting and transport of proteins. GLG1 interacts with glycoproteins containing high mannose aiding their retention until they mature and are fully processed. Its expression is observed not only in most cell types but also prominently in tissues with high secretion activity.
Biological function summary
The function of GLG1 involves participating in the formation and maintenance of the Golgi structure. It is part of the larger protein complex responsible for trafficking glycoproteins within the cell. GLG1 collaborates with other proteins within the Golgi to ensure proper processing and modification of proteins by glycosylation. This involvement makes GLG1 critical in regulating protein quality control and maintaining organelle integrity within cells.
Pathways
The function of GLG1 integrates into the secretory and endoplasmic reticulum-to-Golgi transport pathways. The target aids in modulating protein folding and sorting processes that are essential for cellular homeostasis. It has functional interactions with other Golgi-related proteins like GM130 and proteins involved in transport such as COPI coated vesicle proteins. It plays a supporting role in vesicular trafficking ensuring that proteins reach their correct cellular destinations.
Dysfunctions or alterations in GLG1 expression are linked to congenital disorders of glycosylation. These disorders occur due to impaired glycoprotein processing and transport. GLG1's involvement in these pathways further implicates it in diseases where protein trafficking and glycosylation are disrupted. Moreover it is linked with diseases involving disrupted Golgi function which could be associated with proteins like GOLPH3 that might also have roles in Golgi-related pathologies.